Table 2.
Clinicopathological characteristics of patients in each ISH group.
| Characteristics | Value | ||||
|---|---|---|---|---|---|
| ISH group 1 | ISH group 2 | ISH group 3 | ISH group 4 | ISH group 5 | |
| Age | |||||
| >60 | 38 | 5 | 0 | 11 | 363 |
| ≤60 | 220 | 24 | 4 | 42 | 982 |
| NAa | 60 | 0 | 0 | 0 | 61 |
| Tumor types | |||||
| IDC | 252 | 28 | 4 | 50 | 1262 |
| ILC | 1 | 0 | 0 | 1 | 29 |
| Special types | 5 | 1 | 0 | 2 | 54 |
| NAa | 60 | 0 | 0 | 0 | 61 |
| Tumor size | |||||
| >2 cm | 127 | 15 | 1 | 20 | 460 |
| ≤2 cm | 94 | 10 | 1 | 15 | 735 |
| NAb | 97 | 4 | 2 | 18 | 211 |
| LN status | |||||
| Positive | 106 | 11 | 1 | 16 | 411 |
| Negative | 115 | 14 | 1 | 19 | 784 |
| NAb | 97 | 4 | 2 | 18 | 211 |
| WHO grade | |||||
| I | 4 | 0 | 0 | 0 | 191 |
| II | 87 | 12 | 0 | 13 | 572 |
| III | 124 | 13 | 2 | 20 | 354 |
| NAb | 103 | 4 | 2 | 20 | 289 |
| Hormone status | |||||
| ER+ | 149 | 20 | 3 | 44 | 1152 |
| ER− | 109 | 9 | 1 | 9 | 193 |
| PR+ | 130 | 16 | 3 | 38 | 1052 |
| PR− | 128 | 13 | 1 | 15 | 293 |
| NAa | 60 | 0 | 0 | 0 | 61 |
ISH: in situ hybridization; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma;. LN: lymph node; WHO: world health organization; ER: estrogen receptor; PR: progesterone receptor.
NAa: not available for cases with missing data on the tumor characteristics. NAb: not available for cases with missing data on the tumor characteristics and not applied for samples from core needle biopsies or metastatic sites.